source
- Phase 1 trial shows safety and early PSA responses for novel PSMA radioligand in mCRPCA Phase 1 study evaluated the long‑circulating PSMA therapeutic radioligand [177Lu]Lu‑D‑Dan‑Phe‑PSMA in patients with metastatic castration‑resistant prostate cancer. The trial enrolled several dos…
- FDA warns of secondary cancers linked to tazemetostat in follicular lymphoma and epithelioid sarcomaThe FDA issued an alert after the voluntary withdrawal of tazemetostat indications for follicular lymphoma and epithelioid sarcoma, emphasizing the drug's association with secondary primary maligna…